Unnamed: 0 int64 0 350k | level_0 int64 0 351k | ApplicationNumber int64 9.75M 96.1M | ArtUnit int64 1.6k 3.99k | Abstract stringlengths 1 8.37k | Claims stringlengths 3 292k | abstract-claims stringlengths 68 293k | TechCenter int64 1.6k 3.9k |
|---|---|---|---|---|---|---|---|
400 | 400 | 15,709,029 | 1,612 | The present invention relates to a dry mouthwash comprising granules that reconstitute in an aqueous solution, such as water, to produce a solution that tastes and functions as a typical liquid mouthwash. | 1. A dry mouthwash granule for reconstitution in an aqueous medium, comprising:
an active component, an organic acid component and a carbonate salt component wherein said granule causes an effervescent reaction to occur upon being combined with said aqueous medium; wherein said granule has a particle size between 53 mi... | The present invention relates to a dry mouthwash comprising granules that reconstitute in an aqueous solution, such as water, to produce a solution that tastes and functions as a typical liquid mouthwash.1. A dry mouthwash granule for reconstitution in an aqueous medium, comprising:
an active component, an organic acid... | 1,600 |
401 | 401 | 14,966,276 | 1,631 | Chemical compositions may be selectively or preferentially excited by the application of scores comprising a series of energy inputs. | 1.-22. (canceled) 23. A method, comprising
identifying a naturally-occurring agent in a body; selecting a set of differing energy inputs specific to the agent, wherein the set of differing energy inputs selectively resonates a plurality of resonant structures in the agent; and directing the set of differing energy inpu... | Chemical compositions may be selectively or preferentially excited by the application of scores comprising a series of energy inputs.1.-22. (canceled) 23. A method, comprising
identifying a naturally-occurring agent in a body; selecting a set of differing energy inputs specific to the agent, wherein the set of differin... | 1,600 |
402 | 402 | 15,897,030 | 1,636 | This document provides methods and materials for treating diabetes. For example, methods and materials for using nucleic acid encoding human preproinsulin to treat diabetes (e.g., type I or type II diabetes) are provided. | 1. A method for treating diabetes, wherein said method comprises administering, to a mammal with diabetes, a vector comprising a nucleic acid construct comprising a nucleic acid encoding an insulin polypeptide and a nucleic acid encoding an inducible death switch polypeptide. 2. The method of claim 1, wherein said mamm... | This document provides methods and materials for treating diabetes. For example, methods and materials for using nucleic acid encoding human preproinsulin to treat diabetes (e.g., type I or type II diabetes) are provided.1. A method for treating diabetes, wherein said method comprises administering, to a mammal with di... | 1,600 |
403 | 403 | 15,551,597 | 1,617 | Disclosed is a cosmetic product comprising a metal can which comprises a metal container (A) which has a rotary thread (A′) and contains a cosmetic preparation as well as a lid (D) having a thread (D′) and being of the same metal as the container. The lid can be screwed onto/unscrewed from the container by means of thr... | 1.-4. (canceled) 5. A cosmetic product, wherein the product comprises a metal can which comprises a metallic container (A) containing a cosmetic preparation (Z) and comprising a rotation thread (A′) and a lid (D) having a thread (D′) and being made of the same metal as the container (A), lid (D) being unscrewable and s... | Disclosed is a cosmetic product comprising a metal can which comprises a metal container (A) which has a rotary thread (A′) and contains a cosmetic preparation as well as a lid (D) having a thread (D′) and being of the same metal as the container. The lid can be screwed onto/unscrewed from the container by means of thr... | 1,600 |
404 | 404 | 14,511,702 | 1,631 | Short fixed length source sub-sequences are extracted from a collection of source sequences derived from a sample for which the biological signature is to be determined. The extracted short fixed length source sub-sequences are compiled to determine the frequency of each within the collection. Overlaps between the shor... | 1-20. (canceled) 21. An article of manufacture comprising a computer readable storage medium for storing computer readable program code which, when executed, causes a computer node to perform the steps of:
extracting short fixed length source sub-sequences from a collection of source sequences derived from a sample for... | Short fixed length source sub-sequences are extracted from a collection of source sequences derived from a sample for which the biological signature is to be determined. The extracted short fixed length source sub-sequences are compiled to determine the frequency of each within the collection. Overlaps between the shor... | 1,600 |
405 | 405 | 14,767,601 | 1,656 | Provided is a collagen sponge which has compressive strength (stress) equivalent to that of a tissue into which the collagen sponge is to be implanted, has no unevenness in structure and stress, and has a pore structure for allowing cells to infiltrate thereinto. The collagen sponge is obtained by subjecting a collagen... | 1. A collagen sponge, which is obtained by subjecting a collagen dispersion, a collagen solution, or a mixture thereof having a collagen concentration of 50 mg/ml or more to freeze-drying and insolubilization treatment thereafter,
wherein the collagen sponge has a stress of from 10 kPa to 30 kPa when loaded with 10% st... | Provided is a collagen sponge which has compressive strength (stress) equivalent to that of a tissue into which the collagen sponge is to be implanted, has no unevenness in structure and stress, and has a pore structure for allowing cells to infiltrate thereinto. The collagen sponge is obtained by subjecting a collagen... | 1,600 |
406 | 406 | 15,621,782 | 1,612 | Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent. Also disclosed are low viscosity delivery systems for administration of active agents... | 1. A composition, comprising: an amide-type local anesthetic, an enolic-acid non-steroidal anti-inflammatory drug (NSAID) and a delivery vehicle. 2. The composition of claim 1, wherein the amide-type local anesthetic is selected from the group consisting of bupivacaine, ropivacaine, levobupivacaine, dibucaine, mepivaca... | Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent. Also disclosed are low viscosity delivery systems for administration of active agents... | 1,600 |
407 | 407 | 15,711,316 | 1,618 | The present invention is directed towards new 18 F-folate radiopharmaceuticals, wherein fluorine-18 is covalently linked to the glutamate portion of a folate or derivative thereof, a method of their preparation, as well as their use in diagnosis and monitoring of therapy of cancer and inflammatory and autoimmune disea... | 1. A compound of formula I,
wherein
P is a pteroyl group or derivative thereof,
Xa, Xb are independently of each other C, N, O, S,
Ra, Rb are independently of each other H or straight-chain or branched C1-C12 alkyl, C3-C6 cycloalkyl, C5-C14 aryl or C5-C14 heteroaryl, which independently of each other are unsu... | The present invention is directed towards new 18 F-folate radiopharmaceuticals, wherein fluorine-18 is covalently linked to the glutamate portion of a folate or derivative thereof, a method of their preparation, as well as their use in diagnosis and monitoring of therapy of cancer and inflammatory and autoimmune disea... | 1,600 |
408 | 408 | 10,564,012 | 1,653 | The present invention is concerned the labelling of biological compounds with stable isotopes such that the three-dimensional structure of the biological compounds may be analysed by e.g. NMR spectroscopy. The invention employs microorganisms that are grown on mineral media comprising carbon and nitrogen sources that c... | 1. A method for producing a nutrient medium for growing mammalian or insect cells in culture whereby for at least one of H, C or N, substantially all atoms in substrates that are used by the cells for synthesis of biomolecules in the nutrient medium are isotopically labelled, whereby the method comprising the steps of:... | The present invention is concerned the labelling of biological compounds with stable isotopes such that the three-dimensional structure of the biological compounds may be analysed by e.g. NMR spectroscopy. The invention employs microorganisms that are grown on mineral media comprising carbon and nitrogen sources that c... | 1,600 |
409 | 409 | 15,565,983 | 1,613 | Emulsifiers for emulsions vaccine formulations and use in water-in-oil emulsion for vaccine formulations as an emulsifier. The emulsifier is an alkoxylated polyol or polyamine which is optionally acyl terminated. There is also provided a method of forming the vaccine formulation. The emulsifiers provide for emulsions w... | 1. A vaccine formulation comprising a water-in-oil emulsion and at least one vaccine antigen, oil, and water, where said emulsion comprises an emulsifier being an alkoxylated polyol or polyamine which is optionally acyl terminated. 2. The formulation according to claim 1, where the emulsifier has a general structure (I... | Emulsifiers for emulsions vaccine formulations and use in water-in-oil emulsion for vaccine formulations as an emulsifier. The emulsifier is an alkoxylated polyol or polyamine which is optionally acyl terminated. There is also provided a method of forming the vaccine formulation. The emulsifiers provide for emulsions w... | 1,600 |
410 | 410 | 15,346,189 | 1,617 | The invention is directed to an aqueous seed coating composition comprising one or more active ingredients, to a pre-blend and use thereof as a component of the seed coating composition, to a method for improving the bio-efficacy of an active ingredient in a seed coating, and to a coated seed.
The seed coating co... | 1. An aqueous seed coating composition comprising a wax, at least one pigment, an optional surface active agent and one or more biologically active ingredients. 2. The seed coating composition according to claim 1, wherein the wax is selected from the group consisting of polyethylene wax, Fischer-Tropsch wax, and carna... | The invention is directed to an aqueous seed coating composition comprising one or more active ingredients, to a pre-blend and use thereof as a component of the seed coating composition, to a method for improving the bio-efficacy of an active ingredient in a seed coating, and to a coated seed.
The seed coating co... | 1,600 |
411 | 411 | 14,663,533 | 1,699 | An ex vivo cell culture sustained release composition, including:
a mixture comprising:
a sustenant; and a non-biodegradable binder; and
a non-biodegradable and water insoluble encapsulant coat that encapsulates the mixture, as defined herein. Also disclosed is a method for sustainab... | 1. An ex vivo cell culture sustained release composition, comprising:
a mixture comprising:
a sustenant in an amount of from 60 to 96 wt %; and
a non-biodegradable binder in an amount of from 1 to 20 wt %; and
a non-biodegradable and water insoluble encapsulant coat that encapsulates the mixture, in an amount of from ... | An ex vivo cell culture sustained release composition, including:
a mixture comprising:
a sustenant; and a non-biodegradable binder; and
a non-biodegradable and water insoluble encapsulant coat that encapsulates the mixture, as defined herein. Also disclosed is a method for sustainab... | 1,600 |
412 | 412 | 12,161,445 | 1,627 | This invention relates to the use of a parenteral formulation comprising an anti-virally effective amount of TMC278 or a pharmaceutically acceptable acid-addition salt thereof, and a carrier, for the manufacture of a medicament for the treatment of a subject being infected with HIV, wherein the formulation is to be adm... | 1. The use of a parenteral formulation comprising an anti-virally effective amount of TMC278 or a pharmaceutically acceptable acid-addition salt thereof, and a carrier, for the manufacture of a medicament for the treatment of a subject infected with HIV, wherein the formulation is to be administered intermittently at a... | This invention relates to the use of a parenteral formulation comprising an anti-virally effective amount of TMC278 or a pharmaceutically acceptable acid-addition salt thereof, and a carrier, for the manufacture of a medicament for the treatment of a subject being infected with HIV, wherein the formulation is to be adm... | 1,600 |
413 | 413 | 14,358,274 | 1,649 | The present invention provides apoaequorin-based compositions and methods for preconditioning neurons in a subject to reduce neuronal injury due to brain ischemia. Methods include the step of administering apoaequorin to neurons in a subject, wherein the apoaequorin initiates a change in cytokine expression levels resu... | 1. A method of preconditioning neurons to reduce neuronal injury due to brain ischemia in a subject, comprising administering apoaequorin to neurons in a subject, wherein the apoaequorin initiates a change in cytokine expression levels resulting in a reduction in neuronal injury due to brain ischemia in the subject, as... | The present invention provides apoaequorin-based compositions and methods for preconditioning neurons in a subject to reduce neuronal injury due to brain ischemia. Methods include the step of administering apoaequorin to neurons in a subject, wherein the apoaequorin initiates a change in cytokine expression levels resu... | 1,600 |
414 | 414 | 15,366,327 | 1,612 | This application provides, among other things, novel aqueous oral care compositions useful for combining and delivering poorly compatible ingredients, for example to deliver effective levels of cationic antibacterial agents in combination with anionic polymers that protect against erosion and staining, by addition of a... | 1. An oral care compositions comprising
a) an orally acceptable acidic polymer; b) an orally acceptable nonionic polymer; c) an effective amount of orally acceptable cationic active agent, in free or orally acceptable salt form; d) a stabilizing amount of a polyamine compound, in free or orally acceptable salt form; an... | This application provides, among other things, novel aqueous oral care compositions useful for combining and delivering poorly compatible ingredients, for example to deliver effective levels of cationic antibacterial agents in combination with anionic polymers that protect against erosion and staining, by addition of a... | 1,600 |
415 | 415 | 14,423,751 | 1,646 | Provided is an antibody with a specificity to an epitope that is a region corresponding to amino acid positions 63-79 or 73-85 of the human protein S100A9. Provided is further an antibody with a specificity to an epitope that is a region corresponding to amino acid positions 55-71 of the human protein S100A8. Provided ... | 1. An immunoglobulin or proteinaceous binding partner having a binding specificity to an epitope of a vertebrate S100A9 protein, wherein the epitope has an amino acid sequence of a region corresponding to (i) the amino acid sequence ranging from amino acid position 63 to amino acid position 79 of the human protein S100... | Provided is an antibody with a specificity to an epitope that is a region corresponding to amino acid positions 63-79 or 73-85 of the human protein S100A9. Provided is further an antibody with a specificity to an epitope that is a region corresponding to amino acid positions 55-71 of the human protein S100A8. Provided ... | 1,600 |
416 | 416 | 15,332,572 | 1,645 | A method and a composition of matter formed in accordance with the method for anchoring and/or impregnation of a biological vehicle with a cargo molecule includes mixing the biological vehicle and the cargo molecule in suspension to create a cargo molecule and biological vehicle mixture, placing the cargo molecule and ... | 1. A method for anchoring and/or impregnating a biological vehicle with a cargo molecule, comprising:
mixing the biological vehicle and the cargo molecule in suspension to create a cargo molecule and biological vehicle mixture; placing the cargo molecule and biological vehicle mixture inside a pressure vessel; subjecti... | A method and a composition of matter formed in accordance with the method for anchoring and/or impregnation of a biological vehicle with a cargo molecule includes mixing the biological vehicle and the cargo molecule in suspension to create a cargo molecule and biological vehicle mixture, placing the cargo molecule and ... | 1,600 |
417 | 417 | 14,767,936 | 1,642 | This invention relates to a method for detecting shed or circulating tumor cells in a biological fluid using labeled pituitary adenylate cyclase activating peptide or vasoactive intestinal peptide. | 1-4. (canceled) 5. A method for detecting shed or circulating tumor cells comprising:
(a) contacting a biological fluid from a subject with a labeled pituitary adenylate cyclase activating peptide (PACAP) having a label or labeled vasoactive intestinal peptide (VIP) having a label; and (b) determining binding of the la... | This invention relates to a method for detecting shed or circulating tumor cells in a biological fluid using labeled pituitary adenylate cyclase activating peptide or vasoactive intestinal peptide.1-4. (canceled) 5. A method for detecting shed or circulating tumor cells comprising:
(a) contacting a biological fluid fro... | 1,600 |
418 | 418 | 14,996,093 | 1,663 | The invention relates to the novel cotton variety designated 14R913B2XF. Provided by the invention are the seeds, plants, plant parts and derivatives of the cotton variety 14R913B2XF. Also provided by the invention are methods of using cotton variety 14R913B2XF and products derived therefrom. Still further provided by ... | 1. A plant of cotton variety 14R913B2XF, wherein a sample of seed of said variety has been deposited under ATCC Accession No. ______. 2. A plant part of the plant of claim 1, wherein the plant part comprises at least one cell of said plant. 3. The plant part of claim 2, further defined as pollen, a meristem, a cell, or... | The invention relates to the novel cotton variety designated 14R913B2XF. Provided by the invention are the seeds, plants, plant parts and derivatives of the cotton variety 14R913B2XF. Also provided by the invention are methods of using cotton variety 14R913B2XF and products derived therefrom. Still further provided by ... | 1,600 |
419 | 419 | 15,655,075 | 1,618 | Disclosed are hair care compositions, such as conditioners, containing a metathesized unsaturated polyol ester; and a gel matrix phase comprising one or more high melting point fatty compounds, a cationic surfactant system an aqueous carrier. The oligomers provide beneficial hair benefits. Also disclosed are methods of... | 1. A hair care composition comprising: (a) from about 0.05% to about 15%, by weight of said hair care composition, of one or more metathesized unsaturated polyol esters, said metathesized unsaturated polyol ester having one or more of the following properties: (i) a free hydrocarbon content, based on total weight of me... | Disclosed are hair care compositions, such as conditioners, containing a metathesized unsaturated polyol ester; and a gel matrix phase comprising one or more high melting point fatty compounds, a cationic surfactant system an aqueous carrier. The oligomers provide beneficial hair benefits. Also disclosed are methods of... | 1,600 |
420 | 420 | 15,655,038 | 1,618 | Disclosed are hair care compositions, such as shampoos, containing an anionic surfactant, an aqueous carrier, and one or more oligomers derived from metathesis of unsaturated polyol esters. The oligomers provide beneficial hair conditioning benefits. Also disclosed are methods of using the hair care compositions. | 1. A hair care composition comprising: a) a metathesized unsaturated polyol ester, said metathesized unsaturated polyol ester having one or more of the following properties: (i) a free hydrocarbon content, based on total weight of metathesized unsaturated polyol ester, of from about 0% to about 5%; (ii) a weight averag... | Disclosed are hair care compositions, such as shampoos, containing an anionic surfactant, an aqueous carrier, and one or more oligomers derived from metathesis of unsaturated polyol esters. The oligomers provide beneficial hair conditioning benefits. Also disclosed are methods of using the hair care compositions.1. A h... | 1,600 |
421 | 421 | 14,784,418 | 1,618 | Suggested is a composition comprising (a) sclareolide and (b1) at least one tyrosinase inhibitor; and/or (b2) at least one sun protection factor; and/or (b3) at least one anti-oxidants; and/or (b4) at least one anti-inflammatory agent; and/or (b5) at least one desquamating agent, on condition that compound a is present... | 1. A composition comprising
(a) sclareolide; and (b1) at least one skin lightening agent; and/or (b2) at least one sun protection factor; and/or (b3) at least one antioxidant; and/or (b4) at least one anti-inflammatory agent; and/or (b5) at least one desquamating agent, on condition the sclareolide is present in an amo... | Suggested is a composition comprising (a) sclareolide and (b1) at least one tyrosinase inhibitor; and/or (b2) at least one sun protection factor; and/or (b3) at least one anti-oxidants; and/or (b4) at least one anti-inflammatory agent; and/or (b5) at least one desquamating agent, on condition that compound a is present... | 1,600 |
422 | 422 | 15,730,565 | 1,627 | Pharmaceutically acceptable single parasiticidal agent compositions of imidacloprid for oral delivery to mammals to systemically control targeted blood-sucking or blood-consuming parasites, such as fleas, ticks and certain species of helminthes and scabies. | 1. A pharmaceutically acceptable composition of a parasiticidally effective, subtoxic amount of imidacloprid for oral delivery to mammals to control blood-sucking or consuming parasites thereon, wherein imidacloprid is the only parasiticidal agent present in the pharmaceutical composition. 2. The composition according ... | Pharmaceutically acceptable single parasiticidal agent compositions of imidacloprid for oral delivery to mammals to systemically control targeted blood-sucking or blood-consuming parasites, such as fleas, ticks and certain species of helminthes and scabies.1. A pharmaceutically acceptable composition of a parasiticidal... | 1,600 |
423 | 423 | 14,233,602 | 1,657 | Method of detecting the presence of thermoduric microorganisms in a product that includes the steps of (i) placing an aliquot A of a product into a vessel 10 equipped with a probe 30 sensitive to a thermoduric microorganism metabolite, (ii) pasteurizing the aliquot A within the vessel 10, (iii) incubating the pasteuriz... | 1. A method of detecting the presence of thermoduric microorganisms in a product, comprising the steps of:
(a) placing an aliquot of the product into a vessel equipped with an optical probe sensitive to a thermoduric microorganism metabolite, (b) pasteurizing the aliquot within the vessel, (c) incubating the pasteurize... | Method of detecting the presence of thermoduric microorganisms in a product that includes the steps of (i) placing an aliquot A of a product into a vessel 10 equipped with a probe 30 sensitive to a thermoduric microorganism metabolite, (ii) pasteurizing the aliquot A within the vessel 10, (iii) incubating the pasteuriz... | 1,600 |
424 | 424 | 14,913,614 | 1,662 | Compositions and methods are provided for genome modification of a target sequence in the genome of a plant or plant cell. The methods and compositions employ a guide RNA/Cas endonuclease system to provide an effective system for modifying or altering target sites within the genome of a plant, plant cell or seed. Also ... | 1. A method for obtaining a progeny plant comprising an altered target site in its plant genome, the method comprising:
a) crossing a first plant comprising at least one Cas endonuclease capable of introducing a double strand break at a target site in the plant genome with a second plant comprising a guide RNA capable ... | Compositions and methods are provided for genome modification of a target sequence in the genome of a plant or plant cell. The methods and compositions employ a guide RNA/Cas endonuclease system to provide an effective system for modifying or altering target sites within the genome of a plant, plant cell or seed. Also ... | 1,600 |
425 | 425 | 14,552,566 | 1,619 | The present invention relates to a method of shaping a fibrous material and treatment compositions therefor. The method comprises providing a treatment composition comprising an active agent and a photocatalyst, applying the treatment composition to the fibrous material to form a treated fibrous material, mechanically ... | 1. A method for shaping fibrous material comprising:
(a) providing a treatment composition, wherein the treatment composition comprises:
(i) an active agent comprising a monoamine, diamine, or polyamine; and
(ii) a photocatalyst;
(b) applying the treatment composition to a fibrous material to form a treated fibrous ma... | The present invention relates to a method of shaping a fibrous material and treatment compositions therefor. The method comprises providing a treatment composition comprising an active agent and a photocatalyst, applying the treatment composition to the fibrous material to form a treated fibrous material, mechanically ... | 1,600 |
426 | 426 | 15,422,314 | 1,655 | Low water tooth pastes contain a variety of plant extracts. The oral or dentifrice compositions containing humectants, abrasive compounds, and a variety of plant extracts, such as rosemary and green tea extracts, along with an additional antioxidant component. Examples of antioxidants include stannous compounds, sodium... | 1. An oral composition comprising
at least one humectant; at least one abrasive compound; at least one plant-derivable compound selected from the group consisting of flavonoids, catechins, polyphenols, and tannins; and less than 10% by weight water. 2. A composition according to claim 1, comprising 0.001% to 5% by weig... | Low water tooth pastes contain a variety of plant extracts. The oral or dentifrice compositions containing humectants, abrasive compounds, and a variety of plant extracts, such as rosemary and green tea extracts, along with an additional antioxidant component. Examples of antioxidants include stannous compounds, sodium... | 1,600 |
427 | 427 | 14,426,014 | 1,627 | The present invention relates to compositions and methods for the treatment of epilepsy and related disorders. More specifically, the present invention relates to novel combinatorial therapies of epilepsy and related disorders. | 1.-10. (canceled) 11. A composition comprising at least acamprosate, or a salt, prodrug, derivative of any chemical purity, or sustained release formulation thereof, for use in the treatment of epilepsy, benign Rolandic epilepsy, frontal lobe epilepsy, infantile spasms, myoclonic epilepsy, absence epilepsy, Lennox-Gast... | The present invention relates to compositions and methods for the treatment of epilepsy and related disorders. More specifically, the present invention relates to novel combinatorial therapies of epilepsy and related disorders.1.-10. (canceled) 11. A composition comprising at least acamprosate, or a salt, prodrug, deri... | 1,600 |
428 | 428 | 14,128,232 | 1,649 | The present invention relates to compositions and methods for treatment of neurological disorders. In particular, the present invention relates to EGFR as a clinical target for treatment of neurological disorders. | 1. A method of treating a subject with a neurological disorder comprising administering to said subject an agent that inhibits at least one biological function of an EGFR polypeptide. 2. The method of claim 1, wherein said subject exhibits symptoms of a neurological disorder and said administering said agent reduces or... | The present invention relates to compositions and methods for treatment of neurological disorders. In particular, the present invention relates to EGFR as a clinical target for treatment of neurological disorders.1. A method of treating a subject with a neurological disorder comprising administering to said subject an ... | 1,600 |
429 | 429 | 14,828,365 | 1,618 | The present invention relates to an eye-drop composition comprising 2-amino-9-[[(1S,2R)-1,2-bis(hydroxymethyl)cyclopropyl]methyl]-1,9-dihydro-6H-Purin-6-one, and the use thereof for the diagnosis and treatment of herpetic eye infections in companion animals. | 1. A composition comprising:
at least 0.1% w/v 2-amino-9-[[(1S,2R)-1,2-bis(hydroxymethyl)cyclopropyl]methyl]-1,9-dihydro-6H-Purin-6-one; and at least 10% w/v of a cyclodextrin. 2. The composition according to claim 1, which is an aqueous solution. 3. The composition according to claim 1 or 2, wherein said composition i... | The present invention relates to an eye-drop composition comprising 2-amino-9-[[(1S,2R)-1,2-bis(hydroxymethyl)cyclopropyl]methyl]-1,9-dihydro-6H-Purin-6-one, and the use thereof for the diagnosis and treatment of herpetic eye infections in companion animals.1. A composition comprising:
at least 0.1% w/v 2-amino-9-[[(1S... | 1,600 |
430 | 430 | 15,421,621 | 1,639 | Laundry care compositions comprising thiophene azo carboxylate fabric shading dyes and methods of treating a textile comprising such laundry care compositions. | 1. A composition comprising a thiophene azo carboxylate dye having the structure of Formula I:
wherein R1 is selected from the group consisting of H and electron-withdrawing groups; wherein R2 is (CH2CH2O)yQ and R3 is (CH2CH2O)y′Q′;
wherein y and y′ are integers independently selected from 1 to 39,
wherein 8≦... | Laundry care compositions comprising thiophene azo carboxylate fabric shading dyes and methods of treating a textile comprising such laundry care compositions.1. A composition comprising a thiophene azo carboxylate dye having the structure of Formula I:
wherein R1 is selected from the group consisting of H an... | 1,600 |
431 | 431 | 14,531,472 | 1,649 | The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other ... | 1. A peptide or a variant peptide comprising an amino acid sequence selected from the group consisting of SEQ ID No. 1 to SEQ ID No. 49, SEQ ID No. 71, and SEQ ID No. 74 to 129, and variant sequences thereof which are at least 90% homologous to SEQ ID No. 1 to SEQ ID No. 49, SEQ ID No. 71, and SEQ ID No. 74 to 129, and... | The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other ... | 1,600 |
432 | 432 | 14,401,668 | 1,613 | An emulsion contains 50 to 90% by weight of an aqueous phase and 10 to 50% by weight of an oil phase containing 30 to 90% by weight of a diluent oil, and at least 10% by weight of at least one polyunsaturated fatty acid and/or derivative thereof. The emulsion has improved stability and/or organoleptic properties and ca... | 1. An emulsion comprising;
(i) 50 to 90% by weight of an aqueous phase, and (ii) 10 to 50% by weight of an oil phase comprising (a) 30 to 90% by weight of a diluent oil, and (b) at least 10% by weight of at least one polyunsaturated fatty acid and/or derivative thereof. 2. The emulsion according to claim 1 wherein the ... | An emulsion contains 50 to 90% by weight of an aqueous phase and 10 to 50% by weight of an oil phase containing 30 to 90% by weight of a diluent oil, and at least 10% by weight of at least one polyunsaturated fatty acid and/or derivative thereof. The emulsion has improved stability and/or organoleptic properties and ca... | 1,600 |
433 | 433 | 15,008,865 | 1,629 | Agents containing (A) cystine or a derivative thereof and (B) theanine, in combination, are useful for reducing side effects of cancer chemotherapy, can reduce various side effects of cancer chemotherapy, and can improve the treatment completion rate of cancer chemotherapy. | 1. An agent for reducing side effects of cancer chemotherapy, comprising:
(A) cystine or a derivative thereof; and (B) theanine,
in combination. 2. The agent according to claim 1, which is a composition comprising (A) cystine or a derivative thereof and (B) theanine. 3. The agent according to claim 1, wherein the weig... | Agents containing (A) cystine or a derivative thereof and (B) theanine, in combination, are useful for reducing side effects of cancer chemotherapy, can reduce various side effects of cancer chemotherapy, and can improve the treatment completion rate of cancer chemotherapy.1. An agent for reducing side effects of cance... | 1,600 |
434 | 434 | 10,830,001 | 1,616 | A cosmetic or dermatological cleansing emulsion having a viscosity of from about 500 to about 3,500 mPas and comprising sodium laureth sulfate and/or sodium myreth sulfate, a polyacrylate, a paraffin oil, and an oil having a polarity of about 5 to about 50 mN/m. This abstract is neither intended to define the invention... | 1. A cosmetic or dermatological cleansing emulsion comprising:
(a) from about 2% to about 17% by weight of at least one of sodium laureth sulfate and sodium myreth sulfate; (b) from about 0.20% to about 0.74% by weight of one or more polyacrylates selected from anionic homopolymers and anionic copolymers of at least ... | A cosmetic or dermatological cleansing emulsion having a viscosity of from about 500 to about 3,500 mPas and comprising sodium laureth sulfate and/or sodium myreth sulfate, a polyacrylate, a paraffin oil, and an oil having a polarity of about 5 to about 50 mN/m. This abstract is neither intended to define the invention... | 1,600 |
435 | 435 | 15,294,225 | 1,616 | Insecticidal compositions suitable for use in preparation of insecticidal liquid fertilizers are disclosed. The compositions include bifenthrin, a polymeric dispersant, a suspension agent, a freeze-thaw stabilizer, and optionally a preservative. | 1. An insecticidal composition comprising:
a) bifenthrin; b) a polymeric dispersant selected from the group consisting of polyacrylic acids, polymethacrylic acids, copolymers thereof, salts thereof, and combinations thereof; c) a suspension agent selected from the group consisting of attapulgite clay, fumed silica, and... | Insecticidal compositions suitable for use in preparation of insecticidal liquid fertilizers are disclosed. The compositions include bifenthrin, a polymeric dispersant, a suspension agent, a freeze-thaw stabilizer, and optionally a preservative.1. An insecticidal composition comprising:
a) bifenthrin; b) a polymeric di... | 1,600 |
436 | 436 | 14,784,798 | 1,612 | A pharmaceutical composition is described that is suitable for delivery from a pressurised container. The composition is preferably free of polar excipients and comprises: (a) a propellant component that consists essentially of 1,1-difluoroethane (R-152a); (b) a surfactant component that comprises at least one surfacta... | 1. A pharmaceutical composition that is free of polar excipients, said composition comprising:
(a) a propellant component consisting essentially of 1,1-difluoroethane (R-152a), (b) a surfactant component consisting entirely of at least one surfactant compound selected from the group consisting of polyvinylpyrrolidone a... | A pharmaceutical composition is described that is suitable for delivery from a pressurised container. The composition is preferably free of polar excipients and comprises: (a) a propellant component that consists essentially of 1,1-difluoroethane (R-152a); (b) a surfactant component that comprises at least one surfacta... | 1,600 |
437 | 437 | 14,913,177 | 1,662 | Compositions and methods are provided for genome modification of a target sequence in the genome of a cell. The methods and compositions employ a guide polynucleotide/Cas endonuclease system to provide an effective system for modifying or altering target sites within the genome of a cell or organism. Once a genomic tar... | 1. A guide polynucleotide comprising:
(i) a first nucleotide sequence domain that is complementary to a nucleotide sequence in a target DNA; and, (ii) a second nucleotide sequence domain that interacts with a Cas endonuclease, wherein the first nucleotide sequence domain and the second nucleotide sequence domain are co... | Compositions and methods are provided for genome modification of a target sequence in the genome of a cell. The methods and compositions employ a guide polynucleotide/Cas endonuclease system to provide an effective system for modifying or altering target sites within the genome of a cell or organism. Once a genomic tar... | 1,600 |
438 | 438 | 13,979,908 | 1,631 | The present invention relates to a method for processing a subject's genomic data comprising (a) obtaining a subject's genomic sequence; (b) reducing the complexity and/or amount of the genomic sequence information; and (c) storing the genomic sequence information of step (b) in a rapidly retrievable form. The present ... | 1. A method for processing a subject's genomic data comprising
(a) obtaining a subject's genomic sequence information; (b) reducing the complexity and amount of said genomic sequence information comprising cropping said genomic sequence information except for the signature data pertaining to a disease or disorder; and ... | The present invention relates to a method for processing a subject's genomic data comprising (a) obtaining a subject's genomic sequence; (b) reducing the complexity and/or amount of the genomic sequence information; and (c) storing the genomic sequence information of step (b) in a rapidly retrievable form. The present ... | 1,600 |
439 | 439 | 16,149,483 | 1,617 | A hygiene product, a hygiene product pod, and a method of using the hygiene product pod, the hygiene product pod including a water soluble envelope and the hygiene product sealed in the envelope. The hygiene product includes a carrier comprising butylene glycol in an amount ranging from about 40 wt % to about 70 wt %, ... | 1. A hygiene product comprising:
a carrier comprising butylene glycol in an amount ranging from about 40 wt % to about 70 wt %, based on the total weight of the hygiene product; and an active agent comprising at least one surfactant. 2. The hygiene product of claim 1, wherein the butylene glycol comprises 1,3-butanedio... | A hygiene product, a hygiene product pod, and a method of using the hygiene product pod, the hygiene product pod including a water soluble envelope and the hygiene product sealed in the envelope. The hygiene product includes a carrier comprising butylene glycol in an amount ranging from about 40 wt % to about 70 wt %, ... | 1,600 |
440 | 440 | 15,036,980 | 1,632 | The purpose of the present invention is to provide a novel urethane decomposing method by which urethane in the environment is treated efficiently and at a low cost, and a urethane decomposing agent. The above purpose is attained by employing a urethane decomposing method including: a step of treating a urethane-contai... | 1. A urethane decomposing method including: a step of treating a urethane-containing material to be treated using an unsaturated fatty acid; and a step of making a microorganism belonging to a Streptomyces genus and exhibiting urethane decomposing function, to act on the material treated using the unsaturated fatty aci... | The purpose of the present invention is to provide a novel urethane decomposing method by which urethane in the environment is treated efficiently and at a low cost, and a urethane decomposing agent. The above purpose is attained by employing a urethane decomposing method including: a step of treating a urethane-contai... | 1,600 |
441 | 441 | 16,149,543 | 1,617 | A hygiene product, a hygiene product pod, and a method of using the hygiene product pod, the hygiene product pod including a water soluble envelope and the hygiene product sealed in the envelope. The hygiene product includes a carrier comprising butylene glycol in an amount ranging from about 40 wt % to about 70 wt %, ... | 1. A method of using a hygiene product pod comprising a water-soluble envelope and a hygiene product sealed in the envelope and comprising an active agent and a carrier comprising butylene glycol in an amount ranging from about 40 wt % to about 70 wt %, based on the total weight of the hygiene product, the method compr... | A hygiene product, a hygiene product pod, and a method of using the hygiene product pod, the hygiene product pod including a water soluble envelope and the hygiene product sealed in the envelope. The hygiene product includes a carrier comprising butylene glycol in an amount ranging from about 40 wt % to about 70 wt %, ... | 1,600 |
442 | 442 | 14,124,826 | 1,631 | Systems and methods are directed to computerized methods and one or more computer processors for quantifying the perturbation of a biological system in response to an agent. A set of treatment data corresponding to a response of a biological system to an agent and a set of control data are received. A computational cau... | 1. A computerized method for quantifying the perturbation of a biological system in response to an agent, comprising
receiving, at a first processor, a set of treatment data corresponding to a response of a biological system to an agent, wherein the biological system includes or comprises a plurality of biological enti... | Systems and methods are directed to computerized methods and one or more computer processors for quantifying the perturbation of a biological system in response to an agent. A set of treatment data corresponding to a response of a biological system to an agent and a set of control data are received. A computational cau... | 1,600 |
443 | 443 | 13,812,073 | 1,627 | The invention provides new therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]-piperazine and pharmaceutically acceptable salts thereof. | 1-8. (canceled) 9. A method for the long-term treatment of a CNS disease comprising the long term administration of a therapeutically effective amount of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof to a patient in need thereof wherein said administration is not asso... | The invention provides new therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]-piperazine and pharmaceutically acceptable salts thereof.1-8. (canceled) 9. A method for the long-term treatment of a CNS disease comprising the long term administration of a therapeutically effective amount of 1-[2-(2,4-dimethyl-p... | 1,600 |
444 | 444 | 13,494,398 | 1,644 | Provided herein, in one aspect, are antibodies that immunospecifically bind to PSGL-1, polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. Also provided herein are kits and pharmaceutical compositions comprising antibodies that s... | 1. A monoclonal antibody which immunospecifically binds to human PSGL-1 comprising:
(i) a variable light (“VL”) chain region comprising the amino acid sequence of SEQ ID NO: 3; (ii) a heavy chain comprising variable heavy (“VH”) chain region comprising the amino acid sequence of SEQ ID NO: 4; and (iii) a human IgG4 con... | Provided herein, in one aspect, are antibodies that immunospecifically bind to PSGL-1, polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. Also provided herein are kits and pharmaceutical compositions comprising antibodies that s... | 1,600 |
445 | 445 | 14,208,348 | 1,613 | Described are transdermal drug delivery systems for the transdermal administration of tertiary amine drugs, such as rivastigmine, fentanyl or rotigotine, comprising a polymer matrix comprising a free base form of the drug and at least one carboxyl group-containing compound. In some embodiments, the systems include a ra... | 1. A transdermal drug delivery system comprising a polymer matrix comprising the free base form of a tertiary amine drug and at least one carboxyl group-containing compound, wherein the relative amounts of free base and carboxyl group-containing compound is such that greater than 50% of the free base is associated with... | Described are transdermal drug delivery systems for the transdermal administration of tertiary amine drugs, such as rivastigmine, fentanyl or rotigotine, comprising a polymer matrix comprising a free base form of the drug and at least one carboxyl group-containing compound. In some embodiments, the systems include a ra... | 1,600 |
446 | 446 | 14,762,064 | 1,618 | An oil-in-water nanoemulsion composition for MRI, comprising an aqueous phase, a lipid phase as nanodroplets comprising an oil and magnetic particles based on an iron compound and covered with one or several C8-C22 fatty acids, and a mixture of surfactants at the interface between the aqueous and lipid phases, the mixt... | 1. An oil-in-water nanoemulsion composition, comprising:
50 to 90% by weight of aqueous phase; 9.5 to 49.5% by weight of lipid phase nanodroplets, wherein the lipid phase nanodroplets comprise an oil and magnetic particles, wherein the oil comprises at least 70% by weight of C6-C18 saturated fatty acid glycerides, and ... | An oil-in-water nanoemulsion composition for MRI, comprising an aqueous phase, a lipid phase as nanodroplets comprising an oil and magnetic particles based on an iron compound and covered with one or several C8-C22 fatty acids, and a mixture of surfactants at the interface between the aqueous and lipid phases, the mixt... | 1,600 |
447 | 447 | 15,010,973 | 1,639 | Provided herein, among other things, is method comprising: a) placing a planar absorbent support comprising an in vitro transcription and translation (IVTT) mix impregnated therein in contact with an array of in situ-assembled expression cassettes; and b) incubating the planar absorbent support and array under conditio... | 1. A method comprising:
a) placing a planar absorbent support comprising an in vitro transcription and translation (IVTT) mix impregnated therein in contact with an array of in situ-assembled expression cassettes; and b) incubating the planar absorbent support and array under conditions by which the expressed cassettes... | Provided herein, among other things, is method comprising: a) placing a planar absorbent support comprising an in vitro transcription and translation (IVTT) mix impregnated therein in contact with an array of in situ-assembled expression cassettes; and b) incubating the planar absorbent support and array under conditio... | 1,600 |
448 | 448 | 14,860,781 | 1,615 | The invention disclosed herein is directed to a porous wound healing foam composition that is made from an extracellular matrix of a mammal, method of making, and method of using. | 1. A method for making a medical foam device, comprising:
(a) solubilizing dehydrated extracellular matrix material obtained from a mammalian tissue in a solution comprising a pH less than 4.0 or a pH greater than 9.0 (b) blending said acidified (pH<4) or basic (pH>9) solubilized extracellular matrix material to form a... | The invention disclosed herein is directed to a porous wound healing foam composition that is made from an extracellular matrix of a mammal, method of making, and method of using.1. A method for making a medical foam device, comprising:
(a) solubilizing dehydrated extracellular matrix material obtained from a mammalian... | 1,600 |
449 | 449 | 12,063,614 | 1,618 | The present invention is directed to an implantable device comprising a biocompatible and biodegradable matrix impregnated with a bioactive complex suitable for selectively targeting the lymphatic system, wherein the bioactive complex comprises one or more particle forming materials and one or more bioactive agents. Th... | 1. An implantable device comprising
a biocompatible and biodegradable matrix impregnated with a bioactive complex suitable for selectively targeting the lymphatic system, wherein the bioactive complex comprises one or more particle forming materials and one or more bioactive agents. 2. The implantable device according ... | The present invention is directed to an implantable device comprising a biocompatible and biodegradable matrix impregnated with a bioactive complex suitable for selectively targeting the lymphatic system, wherein the bioactive complex comprises one or more particle forming materials and one or more bioactive agents. Th... | 1,600 |
450 | 450 | 15,478,437 | 1,643 | Activation of 5-HT 2A receptors using agonists at surprisingly low concentrations was shown to potently inhibit TNF-α-induced inflammation in multiple cell types. Significantly, proinflammatory markers were also inhibited by the agonist, (R)-DOI, even many hours after treatment with TNF-α. With the exception of a few ... | 1. A method for the treatment of an inflammatory disorder in a mammal, said method comprising administering to a mammal in need of such treatment an therapeutically effective amount of a 5-HT2A receptor agonist in an amount no greater than that required to result in a body fluid concentration no greater than 5 nM in a ... | Activation of 5-HT 2A receptors using agonists at surprisingly low concentrations was shown to potently inhibit TNF-α-induced inflammation in multiple cell types. Significantly, proinflammatory markers were also inhibited by the agonist, (R)-DOI, even many hours after treatment with TNF-α. With the exception of a few ... | 1,600 |
451 | 451 | 14,442,340 | 1,613 | Curable antifouling compositions include fluorinated polymers that contain a perfluoropolyether group, a poly(alkyleneoxide) group, a hydrolyzable silane group and a cationic curative. The curable antifouling compositions can be applied on a surface of a substrate, and at least partially cured to provide an article wit... | 1-18. (canceled) 19. A curable antifouling composition comprising components:
a) at least one fluorinated polymer, wherein each said at least one fluorinated polymer independently comprises:
at least one divalent group A represented by the formula
wherein R1 independently represents H or methyl, X indepen... | Curable antifouling compositions include fluorinated polymers that contain a perfluoropolyether group, a poly(alkyleneoxide) group, a hydrolyzable silane group and a cationic curative. The curable antifouling compositions can be applied on a surface of a substrate, and at least partially cured to provide an article wit... | 1,600 |
452 | 452 | 13,603,335 | 1,627 | The present invention relates to a thermodynamically stable, biocompatible, environment friendly, and temperature-insensitive microemulsion containing various botanical essential oils, sugar based surfactants, polyhydric alcohols, and an aqueous phase. | 1. A microemulsion for a topical cosmetic or a pharmaceutical application, said microemulsion comprising:
(a) 1% to 20% w/w of a sugar-based surfactant selected from the group consisting of a sucrose ester, an alkyl polyglucoside and a combination thereof; (b) 1% to 10% w/w of a polyhydric alcohol; (c) 0.5% to 10% w/w ... | The present invention relates to a thermodynamically stable, biocompatible, environment friendly, and temperature-insensitive microemulsion containing various botanical essential oils, sugar based surfactants, polyhydric alcohols, and an aqueous phase.1. A microemulsion for a topical cosmetic or a pharmaceutical applic... | 1,600 |
453 | 453 | 15,146,020 | 1,628 | The synthesis, growth inhibition and radioprotective activity of the PrC-210 aminothiol, 3-(methyl-amino)-2-((methylamino)methyl)propane-l-thiol, and its polyamine and thiolated polyamine progenitors are reported. All of the molecules significantly inhibited growth of cultured normal human fibroblasts. The combination ... | 1. A method for protecting a subject from ionizing radiation, the method comprising:
administering systemically to the subject a radioprotector compound comprising a free thiol and a positively-charged backbone, wherein the radioprotector compound comprises a structure according to:
wherein R and R′ are ind... | The synthesis, growth inhibition and radioprotective activity of the PrC-210 aminothiol, 3-(methyl-amino)-2-((methylamino)methyl)propane-l-thiol, and its polyamine and thiolated polyamine progenitors are reported. All of the molecules significantly inhibited growth of cultured normal human fibroblasts. The combination ... | 1,600 |
454 | 454 | 15,586,578 | 1,618 | A composition includes a therapeutically effective oral pharmaceutical dosage form that becomes buoyant upon contact with gastric fluid. The dosage form includes an active ingredient combination including an amino acid source and a zinc source, an anionic polymer, an effervescent agent, and a pH buffer. The dosage form... | 1. A composition comprising:
a therapeutically effective oral pharmaceutical dosage form that becomes buoyant upon contact with gastric fluid, the dosage form having therein: an active ingredient combination including an amino acid source and a zinc source; an anionic polymer; an effervescent agent; and a pH buffer; wh... | A composition includes a therapeutically effective oral pharmaceutical dosage form that becomes buoyant upon contact with gastric fluid. The dosage form includes an active ingredient combination including an amino acid source and a zinc source, an anionic polymer, an effervescent agent, and a pH buffer. The dosage form... | 1,600 |
455 | 455 | 13,310,632 | 1,612 | This invention relates to rapidly dispersing microgranules comprising at least one sugar alcohol or saccharide, at least one super disintegrant, and a pharmaceutically acceptable additive with multi-functionality (e.g., starch acting as a binder, disintegrant, diluent/filler, glidant, etc) at a low level, which can be ... | 1. Rapidly dispersing microgranules with a median particle size in the range of about 100 μm to about 300 μm, comprising at least one sugar alcohol, saccharide, or a mixture thereof, at least one super disintegrant, and at least one multifunctional additive. 2. The microgranules of claim 1 wherein the at least one suga... | This invention relates to rapidly dispersing microgranules comprising at least one sugar alcohol or saccharide, at least one super disintegrant, and a pharmaceutically acceptable additive with multi-functionality (e.g., starch acting as a binder, disintegrant, diluent/filler, glidant, etc) at a low level, which can be ... | 1,600 |
456 | 456 | 15,347,996 | 1,636 | Disclosed are delivery platforms for use in gene editing that include a relatively short, highly efficient promoter that drives transcription of a nucleic acid sequence that encodes a gene-editing molecule, e.g., either a gRNA or a nuclease. In conjunction with this promoter, the vector includes one or more transcripti... | 1. A viral vector comprising:
one or more structural components derived from a virus; a nucleic acid sequence encoding a gene-editing molecule; a promoter configured to initiate transcription of the nucleic acid sequence encoding the gene-editing molecule, wherein the promoter is free of introns; an Sp1 transcription f... | Disclosed are delivery platforms for use in gene editing that include a relatively short, highly efficient promoter that drives transcription of a nucleic acid sequence that encodes a gene-editing molecule, e.g., either a gRNA or a nuclease. In conjunction with this promoter, the vector includes one or more transcripti... | 1,600 |
457 | 457 | 14,540,754 | 1,615 | A composition intended to be employed for therapeutic purposes incorporates a nicotinic compound, a sugar substitute, and a sugar alcohol syrup. Representative forms of nicotine include free base (e.g., as a mixture of nicotine and microcrystalline cellulose), a nicotine salt (e.g., as nicotine bitartrate) or nicotine ... | 1-27. (canceled) 28. A method of preparing a nicotine-containing pharmaceutical composition, comprising:
(i) mixing a non-hygroscopic sugar substitute capable of forming a glassy matrix in an amount of at least about 80% by weight and a sugar alcohol syrup in a melted state to form a mixture; (ii) cooling the mixture a... | A composition intended to be employed for therapeutic purposes incorporates a nicotinic compound, a sugar substitute, and a sugar alcohol syrup. Representative forms of nicotine include free base (e.g., as a mixture of nicotine and microcrystalline cellulose), a nicotine salt (e.g., as nicotine bitartrate) or nicotine ... | 1,600 |
458 | 458 | 15,198,248 | 1,612 | A method of making a consumer product providing multiple blooms of fragrance, the multiple blooms being provided for by different populations of microcapsules. | 1. A method of making a consumer product that provides multiple blooms of fragrance, the method comprising:
combining a first adjunct material, a first population of microcapsules, and a second population of microcapsules to form the consumer product; wherein the first population has a first median volume weighted part... | A method of making a consumer product providing multiple blooms of fragrance, the multiple blooms being provided for by different populations of microcapsules.1. A method of making a consumer product that provides multiple blooms of fragrance, the method comprising:
combining a first adjunct material, a first populatio... | 1,600 |
459 | 459 | 15,152,835 | 1,615 | Crystalline microparticles consisting of a phenylalkylamino beta 2 -adrenergic agonist coated with a C12-C20 fatty acid are useful for the preparation of pharmaceutical aerosol formulations in form of suspension in a liquefied propellant gas or powder formulations. | 1-11. (canceled) 12. A process for preparing chemically stable crystalline microparticles, comprising a beta2-adrenergic agonist selected from the group consisting of formoterol, a pharmaceutically acceptable salt of formoterol, indacaterol, and a pharmaceutically acceptable salt of indacaterol, coated with at least on... | Crystalline microparticles consisting of a phenylalkylamino beta 2 -adrenergic agonist coated with a C12-C20 fatty acid are useful for the preparation of pharmaceutical aerosol formulations in form of suspension in a liquefied propellant gas or powder formulations.1-11. (canceled) 12. A process for preparing chemically... | 1,600 |
460 | 460 | 12,456,567 | 1,617 | This invention relates to a storage stable, aqueous, herbicidal formulation containing an ultra-high concentration of glyphosate in the isopropylamine, potassium or mixed salt form in combination with a surfactant system, to a method of making the formulation, and to a method of treating unwanted vegetation employing t... | 1. An ultra-high load, aqueous glyphosate salt-containing concentrate comprising:
a. water; b. glyphosate salt in solution in the water in an amount greater than about 39 weight percent of acid equivalent, based on the weight of the concentrate, said glyphosate salt being selected from the group consisting of the isopr... | This invention relates to a storage stable, aqueous, herbicidal formulation containing an ultra-high concentration of glyphosate in the isopropylamine, potassium or mixed salt form in combination with a surfactant system, to a method of making the formulation, and to a method of treating unwanted vegetation employing t... | 1,600 |
461 | 461 | 14,020,205 | 1,627 | The invention generally pertains to the discovery that agents capable of inhibiting the binding of cortisol to its receptor can be used in methods for treating patients diagnosed with Amyotrophic Lateral Sclerosis (ALS). | 1. A method for ameliorating the symptoms and/or slowing the rate of disease progression in a patient diagnosed with amyotrophic lateral sclerosis (ALS), the method comprising administering a therapeutically effective amount of a glucocorticoid receptor specific antagonist (GRA) to a subject in need thereof, with the p... | The invention generally pertains to the discovery that agents capable of inhibiting the binding of cortisol to its receptor can be used in methods for treating patients diagnosed with Amyotrophic Lateral Sclerosis (ALS).1. A method for ameliorating the symptoms and/or slowing the rate of disease progression in a patien... | 1,600 |
462 | 462 | 14,388,115 | 1,615 | Provided is a pharmaceutical composition having a single dosage form including a compartment including olmesartan medoxomil; and a compartment including rosuvastatin or its salt, wherein said compartments are formulated in a separate form. In the pharmaceutical composition of the present invention, olmesartan medoxomil... | 1. A pharmaceutical composition having a single dosage form comprising a compartment comprising olmesartan medoxomil; and a compartment comprising rosuvastatin or its salt, wherein said compartments are formulated in a separate form. 2. The pharmaceutical composition according to claim 1, having a double-layered tablet... | Provided is a pharmaceutical composition having a single dosage form including a compartment including olmesartan medoxomil; and a compartment including rosuvastatin or its salt, wherein said compartments are formulated in a separate form. In the pharmaceutical composition of the present invention, olmesartan medoxomil... | 1,600 |
463 | 463 | 15,366,278 | 1,619 | Hair treatment agents including: at least one anionic surfactant from the group of alkyl sulfates and/or alkyl ether sulfates; at least one amphoteric and/or nonionic surfactant; at least one divalent or trivalent metal salt; at least one cationic polymer; and ethyl lauroyl arginate. | 1. A hair treatment agent, comprising:
at least one anionic surfactant from the group of alkyl sulfates and/or alkyl ether sulfates, at least one amphoteric and/or nonionic surfactant, at least one divalent or trivalent metal salt, at least one cationic polymer, and ethyl lauroyl arginate. 2. The agent of claim 1, wher... | Hair treatment agents including: at least one anionic surfactant from the group of alkyl sulfates and/or alkyl ether sulfates; at least one amphoteric and/or nonionic surfactant; at least one divalent or trivalent metal salt; at least one cationic polymer; and ethyl lauroyl arginate.1. A hair treatment agent, comprisin... | 1,600 |
464 | 464 | 14,383,010 | 1,611 | The present invention provides a sunscreen composition comprising two or more oil-soluble ultraviolet absorbers and composite silicone particles having an average particle diameter of 10 μm or less. | 1. A sunscreen composition comprising two or more oil-soluble ultraviolet absorbers and composite silicone particles having an average particle diameter of 10 μm or less. 2. The sunscreen composition according to claim 1, wherein the oil-soluble ultraviolet absorbers are at least two members selected from the group con... | The present invention provides a sunscreen composition comprising two or more oil-soluble ultraviolet absorbers and composite silicone particles having an average particle diameter of 10 μm or less.1. A sunscreen composition comprising two or more oil-soluble ultraviolet absorbers and composite silicone particles havin... | 1,600 |
465 | 465 | 15,800,719 | 1,617 | The present invention concerns a dialysis acid precursor composition for use during preparation of a dialysis acid concentrate solution and for mixing with water, a sodium containing concentrate, and a bicarbonate containing concentrate into a ready-for-use dialysis solution. The dialysis acid precursor composition con... | 1. A dialysis acid precursor composition product comprising:
an anhydrous powdered composition including a sodium containing concentrate, a bicarbonate containing concentrate, a dry acid and a magnesium salt, and a sealed moisture-resistant container housing the anhydrous powdered composition, wherein the container has... | The present invention concerns a dialysis acid precursor composition for use during preparation of a dialysis acid concentrate solution and for mixing with water, a sodium containing concentrate, and a bicarbonate containing concentrate into a ready-for-use dialysis solution. The dialysis acid precursor composition con... | 1,600 |
466 | 466 | 14,510,912 | 1,633 | The method of making a compressed biocomposite body includes compressing a mass of biocomposite material comprised of discrete particles and a network of interconnected glucan-containing mycelia cells in the presence of heat and moisture into a compressed body having a density in excess of 18 pcf. Compression may take ... | 1. A method of making a composite body comprising the steps of
obtaining a mass of biocomposite material comprised of discrete particles, a network of interconnected glucan-containing mycelia cells extending around the discrete particles and a moisture content of from 45% to 70%; placing the biocomposite material in a ... | The method of making a compressed biocomposite body includes compressing a mass of biocomposite material comprised of discrete particles and a network of interconnected glucan-containing mycelia cells in the presence of heat and moisture into a compressed body having a density in excess of 18 pcf. Compression may take ... | 1,600 |
467 | 467 | 15,273,098 | 1,617 | A hydrogel delivery composition, including degradable microcapsules suspended in a degradable thermo-responsive hydrogel. The hydrogel is thermo-responsive at a physiological temperature and changes after application to a more solid state due to body temperatures. The composition includes one or more treatment agents t... | 1. A delivery composition, comprising degradable microcapsules suspended in a degradable thermo-responsive hydrogel, wherein the hydrogel is thermo-responsive at a physiological temperature of about 32° C. to about 37° C. 2. The composition of claim 1, wherein the microcapsules encapsulate and release a treatment agent... | A hydrogel delivery composition, including degradable microcapsules suspended in a degradable thermo-responsive hydrogel. The hydrogel is thermo-responsive at a physiological temperature and changes after application to a more solid state due to body temperatures. The composition includes one or more treatment agents t... | 1,600 |
468 | 468 | 15,202,378 | 1,631 | The invention provides an unbiased method to assess the binding of a test compound to a multiplicity of proteins in the same sample, including samples from living cells by applying the unbiased determination technique of SWATH-MS or the biased technique of SRM-MS to a thermal shift assay to evaluate drug target interac... | 1. A multiplexed method to identify proteins to which a test compound binds in a sample containing numerous proteins or for identifying a compound capable of binding to a target protein contained in a sample comprising numerous proteins, including said target protein, which method comprises:
(a) subjecting a first port... | The invention provides an unbiased method to assess the binding of a test compound to a multiplicity of proteins in the same sample, including samples from living cells by applying the unbiased determination technique of SWATH-MS or the biased technique of SRM-MS to a thermal shift assay to evaluate drug target interac... | 1,600 |
469 | 469 | 15,106,064 | 1,631 | The invention relates to a computer implemented method of analysing data comprising measured values of characteristics of objects in samples, the data comprising —a first set of data (X ireference ) with measured values of characteristics of objects in reference samples; —a test set of data (X itest ) with measured val... | 1.-17. (canceled) 18. Computer implemented method of analysing data comprising measured values of characteristics of objects in samples, the data stored on a computer readable medium comprising
a first set of data (Xi reference ) with measured values of characteristics of objects in reference samples; a test set of da... | The invention relates to a computer implemented method of analysing data comprising measured values of characteristics of objects in samples, the data comprising —a first set of data (X ireference ) with measured values of characteristics of objects in reference samples; —a test set of data (X itest ) with measured val... | 1,600 |
470 | 470 | 14,894,083 | 1,612 | The present invention relates to a drawn antimicrobial, such as an antibacterial, antiparasitic and antiviral polymeric fiber and materials containing same, wherein the fiber is a polymeric fiber containing cuprous iodide particles dispersed therein of about 0.50 to about 2.0 micron in size. The invention also provides... | 1. An antimicrobial fiber comprising a polymer and cuprous iodide particles dispersed therein, wherein said particle size of the cuprous iodide particles ranges from about 0.50 to about 2.0 micron. 2. The antimicrobial fiber of claim 1, wherein at least 80% of cuprous iodide particles within said antimicrobial fiber ha... | The present invention relates to a drawn antimicrobial, such as an antibacterial, antiparasitic and antiviral polymeric fiber and materials containing same, wherein the fiber is a polymeric fiber containing cuprous iodide particles dispersed therein of about 0.50 to about 2.0 micron in size. The invention also provides... | 1,600 |
471 | 471 | 16,166,893 | 1,624 | This invention provides efficient and scalable enantioselective methods that yield 2-alkyl-2-allylcycloalkyanone compounds with quaternary stereogenic centers. Methods include the method for the preparation of a compound of formula (I):
... | 1-40. (canceled) 41. A method for the preparation of a compound of formula (I):
the preparing comprising treating, with a Pd(II) catalyst in an organic solvent,
(i) a compound of formula (II) or (III) or a salt thereof:
or
(ii) a compound of formula (IV) or (V) or a salt thereof:
and ... | This invention provides efficient and scalable enantioselective methods that yield 2-alkyl-2-allylcycloalkyanone compounds with quaternary stereogenic centers. Methods include the method for the preparation of a compound of formula (I):
... | 1,600 |
472 | 472 | 14,563,866 | 1,633 | Methods are provided herein for modifying antigenic carbohydrate epitopes within a xenographic bioprosthetic tissue by oxidation of vicinal diols to form aldehydes or acids and subsequence reductive amination of aldehydes to form stable secondary amines, or amidation or esterification of acids to form stable amides or ... | 1. A method for improving the performance of a bioprosthetic implant, the method comprising:
treating a bioprosthetic tissue with an oxidizing agent that selectively oxidizes antigenic carbohydrates having vicinal diols to produce free aldehyde or acid moieties on the antigenic carbohydrate. 2. The method of claim 1, f... | Methods are provided herein for modifying antigenic carbohydrate epitopes within a xenographic bioprosthetic tissue by oxidation of vicinal diols to form aldehydes or acids and subsequence reductive amination of aldehydes to form stable secondary amines, or amidation or esterification of acids to form stable amides or ... | 1,600 |
473 | 473 | 13,645,595 | 1,612 | A pharmaceutical dosage form for oral administration having a breaking strength of at least 300 N and comprising an opioid agonist, an opioid antagonist, and a polyalkylene oxide having an average molecular weight of at least 200,000 g/mol, wherein in accordance with Ph. Eur. the in vitro release profile of the opioid ... | 1. A pharmaceutical dosage form for oral administration having a breaking strength of at least 300 N and comprising an opioid agonist, an opioid antagonist, and a polyalkylene oxide having an average molecular weight of at least 200,000 g/mol, wherein in accordance with Ph. Eur. the in vitro release profile of the opio... | A pharmaceutical dosage form for oral administration having a breaking strength of at least 300 N and comprising an opioid agonist, an opioid antagonist, and a polyalkylene oxide having an average molecular weight of at least 200,000 g/mol, wherein in accordance with Ph. Eur. the in vitro release profile of the opioid ... | 1,600 |
474 | 474 | 13,982,470 | 1,631 | The present invention relates to a method of discovering pharmacogenomic biomarkers that are correlated with varied individual responses (efficacy, adverse effect, and other end points) to therapeutic agents. The present invention provides a mean to utilize archived clinical samples to perform genome-wide association s... | 1. A method to identify one or more pharmacogenomic biomarkers, which method comprises:
a) isolating DNA from archived clinical samples of at least two patients exhibiting different values in a relevant phenotype; b) amplifying said isolated DNA; c) obtaining high-density genotyping data of said amplified DNA; and d) p... | The present invention relates to a method of discovering pharmacogenomic biomarkers that are correlated with varied individual responses (efficacy, adverse effect, and other end points) to therapeutic agents. The present invention provides a mean to utilize archived clinical samples to perform genome-wide association s... | 1,600 |
475 | 475 | 14,938,663 | 1,616 | This invention relates to a “high lower alcohol content”(>40% v/v of a C 1-4 alcohol) liquid composition able to be dispensed as a stable foam with the use of non-propellant foam dispensing devices from non-pressurized containers. The liquid compositions comprise an alcohol, C 1-4 (>40% v/v), a silicone-based surfact... | 1. A foamable alcohol composition, comprising;
a) at least one C1-4 alcohol, or mixtures thereof, present in an amount greater than about 40% v/v of the total composition; b) at least one effective physiologically acceptable silicone-based surface active agent, which includes a lipophilic chain containing a silicone ba... | This invention relates to a “high lower alcohol content”(>40% v/v of a C 1-4 alcohol) liquid composition able to be dispensed as a stable foam with the use of non-propellant foam dispensing devices from non-pressurized containers. The liquid compositions comprise an alcohol, C 1-4 (>40% v/v), a silicone-based surfact... | 1,600 |
476 | 476 | 13,892,805 | 1,633 | Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding ... | 1) A method of preparing T-cells for immunotherapy comprising
(a) modifying T-cells by inactivating at least:
a first gene expressing a target for an immunosuppressive agent, and
a second gene encoding a component of a T-cell receptor (TCR); and
(b) expanding said cells, optionally in presence of said immunosuppressiv... | Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding ... | 1,600 |
477 | 477 | 14,684,242 | 1,631 | Provided herein are methods for simultaneously identifying genomic copy number variations (CNVs) and sequence variations in an enriched genomic sample and compositions, systems, and kits for performing such methods. In some aspects, the methods include: (a) obtaining a plurality of sequence reads from an enriched genom... | 1. A method for detecting genomic alterations, comprising:
(a) obtaining a plurality of sequence reads from an enriched genomic sample that includes a plurality of genomic backbone regions and a plurality of genomic mutation regions of interest in a genomic locus of a subject; (b) obtaining a plurality of sequence read... | Provided herein are methods for simultaneously identifying genomic copy number variations (CNVs) and sequence variations in an enriched genomic sample and compositions, systems, and kits for performing such methods. In some aspects, the methods include: (a) obtaining a plurality of sequence reads from an enriched genom... | 1,600 |
478 | 478 | 15,408,924 | 1,611 | An avermectin-based topical formulation is disclosed which is useful for prevention and treatment of head lice ( Pediculus humanus capitis ). This topical formulation may be formulated as a shampoo-condition which comprises an effective amount of avermectin, solubilizers, suspending agents, preservatives, nonionic surf... | 1.-20. (canceled) 21. A method for the treatment or prophylaxis of a lice infestation, the method comprising:
(a) applying to an area of a human a topical pediculicidal formulation comprising
about 0.1% to about 2.0% by weight ivermectin,
a solubilizer,
about 20% to 30% by weight olive oil,
a non-ionic surfactant, and
... | An avermectin-based topical formulation is disclosed which is useful for prevention and treatment of head lice ( Pediculus humanus capitis ). This topical formulation may be formulated as a shampoo-condition which comprises an effective amount of avermectin, solubilizers, suspending agents, preservatives, nonionic surf... | 1,600 |
479 | 479 | 13,386,111 | 1,653 | The present invention relates to a method of processing allograft skin for transplantation and a cryopreserved allograft skin produced thereby. More specifically, the present invention relates to a method in which a cryoprotectant is prepared by adding sucrose to basic constituents comprising dimethyl sulfoxide, an ani... | 1. A method of processing allograft skin for transplantation comprising:
i) mixing dimethyl sulfoxide, an animal cell culture medium and fetal bovine serum; ii) dissolving sucrose in the solution to obtain a cryoprotectant; iii) penetrating the cryoprotectant into a separated skin; and iv) freezing the cryoprotectant-p... | The present invention relates to a method of processing allograft skin for transplantation and a cryopreserved allograft skin produced thereby. More specifically, the present invention relates to a method in which a cryoprotectant is prepared by adding sucrose to basic constituents comprising dimethyl sulfoxide, an ani... | 1,600 |
480 | 480 | 12,129,935 | 1,627 | The present invention provides 4-anilino-3-quinolinecarbonitriles compounds useful for treating a subject having an BcrAbl positive leukemia that is resistant to imatinib. | 1. A method for treating a BcrAbl positive leukemia in a subject that is resistant to imatinib which comprises administering to the subject a therapeutically effective amount of a compound of the Formula:
wherein:
n is 1, 2 or 3;
X is N or CH, provided that when X is N, then n is 2 or 3;
R is alkyl of from 1... | The present invention provides 4-anilino-3-quinolinecarbonitriles compounds useful for treating a subject having an BcrAbl positive leukemia that is resistant to imatinib.1. A method for treating a BcrAbl positive leukemia in a subject that is resistant to imatinib which comprises administering to the subject a therape... | 1,600 |
481 | 481 | 15,226,126 | 1,643 | The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other ... | 1. A peptide consisting of the amino acid sequence of SEQ ID NO: 21, or a pharmaceutically acceptable salt thereof. 2. A fusion protein comprising the peptide of SEQ ID NO: 21 adjoined at the N-terminus and/or the C-terminus by one or more heterologous peptides, or a pharmaceutically acceptable salt thereof. 3. A kit c... | The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other ... | 1,600 |
482 | 482 | 15,226,098 | 1,643 | The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other ... | 1. A peptide consisting of the amino acid sequence of SEQ ID NO: 1, or a pharmaceutically acceptable salt thereof. 2. A fusion protein comprising the peptide of SEQ ID NO: 1 adjoined at the N-terminus and/or the C-terminus by one or more heterologous peptides, or a pharmaceutically acceptable salt thereof. 3. A kit com... | The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other ... | 1,600 |
483 | 483 | 15,887,164 | 1,634 | Disclosed are nucleic acid molecules from the genome of Dirofilaria spp. nematodes that contain single nucleotide polymorphisms related to reduced responsiveness of the nematodes to macrocyclic lactones. In one example, the species of Dirofilaria is Dirofilaria immitis (the agent of heartworm in animals). Also di... | 1.-12. (canceled) 13. An isolated nucleic acid molecule comprising 5-300 nucleotides of a sequence selected from the group consisting of SEQ ID NOs: 1-113 and 115-127, or a reverse complement thereof,
wherein the oligonucleotide includes a disclosed polymorphic site that correlates with resistance to a macrocyclic lact... | Disclosed are nucleic acid molecules from the genome of Dirofilaria spp. nematodes that contain single nucleotide polymorphisms related to reduced responsiveness of the nematodes to macrocyclic lactones. In one example, the species of Dirofilaria is Dirofilaria immitis (the agent of heartworm in animals). Also di... | 1,600 |
484 | 484 | 14,438,718 | 1,612 | Encapsulated bitter peptides, methods of encapsulating bitter peptides, and nutritional compositions including encapsulated bitter peptides are provided. The bitter peptides can be encapsulated in a hydrophobic matrix, such as an organogel, a solid lipid nanoparticle, a liposome or combinations thereof. The encapsulate... | 1. A nutritional composition comprising bitter peptides encapsulated in a structure selected from the group consisting of organogels, liposomes, solid lipid nanoparticles and combinations thereof. 2. The nutritional composition of claim 1, wherein the structure is an organogel comprising an oil or melted fat and a gela... | Encapsulated bitter peptides, methods of encapsulating bitter peptides, and nutritional compositions including encapsulated bitter peptides are provided. The bitter peptides can be encapsulated in a hydrophobic matrix, such as an organogel, a solid lipid nanoparticle, a liposome or combinations thereof. The encapsulate... | 1,600 |
485 | 485 | 15,010,549 | 1,653 | The claimed subject matter comprises a device to collect and preserve cells comprising of: (1) a collection container comprised of a tube having an open end and a closed end, a closure in the open end of the tube, a vacuum drawn to a predetermined level inside the container; and (2) compounds including an anticoagulant... | 1-27. (canceled) 28. A method of inhibiting cellular aggregation in a biologically active sample comprising mixing an effective amount of diazolidinyl urea with a sample of viable cells, wherein the effective amount of diazolidinyl urea is in a concentration that is less than about 2:100 upon mixing with the sample of ... | The claimed subject matter comprises a device to collect and preserve cells comprising of: (1) a collection container comprised of a tube having an open end and a closed end, a closure in the open end of the tube, a vacuum drawn to a predetermined level inside the container; and (2) compounds including an anticoagulant... | 1,600 |
486 | 486 | 13,891,562 | 1,632 | Described herein are compositions comprising decellularized cardiac extracellular matrix and therapeutic uses thereof. Methods for treating, repairing or regenerating defective, diseased, damaged or ischemic cells, tissues or organs in a subject, preferably a human, using a decellularized cardiac extracellular matrix o... | 1. A composition comprising decellularized extracellular matrix derived from cardiac or skeletal muscle tissue, wherein said decellularized extracellular matrix retains native tissue specific proteins and glycosaminoglycans, and wherein said composition is in a solution form at a temperature between 20° C-25° C. and in... | Described herein are compositions comprising decellularized cardiac extracellular matrix and therapeutic uses thereof. Methods for treating, repairing or regenerating defective, diseased, damaged or ischemic cells, tissues or organs in a subject, preferably a human, using a decellularized cardiac extracellular matrix o... | 1,600 |
487 | 487 | 13,996,097 | 1,642 | Disclosed are CD39 antagonists that can inhibit the immunosuppressive effect of a CD39-expressing cancerous cell, and methods of using the CD39 antagonists. | 1. A method for inhibiting the immunosuppressive effects of a CD39-expressing cancerous cell, comprising contacting said cancerous cell with a CD39 antagonist. 2. The method according to claim 1, wherein said cancerous cell is selected from haematological cancer cells, melanoma cells, ovarian cancer, thyroid cancer, lu... | Disclosed are CD39 antagonists that can inhibit the immunosuppressive effect of a CD39-expressing cancerous cell, and methods of using the CD39 antagonists.1. A method for inhibiting the immunosuppressive effects of a CD39-expressing cancerous cell, comprising contacting said cancerous cell with a CD39 antagonist. 2. T... | 1,600 |
488 | 488 | 12,640,913 | 1,653 | The present invention relates to apparatus, methods, and applications for treating wastewater, and more particularly to biological processes for removing pollutants from wastewater. This invention further relates to apparatus and methods for growing microbes on-site at a wastewater treatment facility, and for economica... | 1-92. (canceled) 93. A method of reducing the amount of settling aid required by a wastewater treatment plant comprising:
providing an on-site system for growing of microbes at the wastewater treatment plant, the on-site system comprising: a main tank, an input for water, an output for a treatment batch, a mixing appar... | The present invention relates to apparatus, methods, and applications for treating wastewater, and more particularly to biological processes for removing pollutants from wastewater. This invention further relates to apparatus and methods for growing microbes on-site at a wastewater treatment facility, and for economica... | 1,600 |
489 | 489 | 13,676,806 | 1,699 | The invention herein comprises amyloid beta-derived diffusible ligands (ADDLs), compositions comprising ADDLs, ADDL-surrogates, ADDL-binding molecules, and methods of using any of the foregoing compounds and compositions. ADDLs comprise amyloid β protein assembled into soluble, globular, non-fibrillar, oligomeric struc... | 1. A method for producing an amyloid beta-derived diffusible ligand (ADDL) neutralizing antibody comprising
(a) injecting ADDLs into an animal to induce an immune response to the ADDLs; (b) isolating antibodies that bind to ADDLs; (c) identifying antibodies of (b) that neutralize ADDL neurotoxicity thereby producing an... | The invention herein comprises amyloid beta-derived diffusible ligands (ADDLs), compositions comprising ADDLs, ADDL-surrogates, ADDL-binding molecules, and methods of using any of the foregoing compounds and compositions. ADDLs comprise amyloid β protein assembled into soluble, globular, non-fibrillar, oligomeric struc... | 1,600 |
490 | 490 | 15,547,067 | 1,617 | Agent for lightening keratin fibers and method for changing the color of keratinic fibers are provided herein. In an embodiment, an agent for lightening keratin fibers includes, relative to the weight thereof, a) from about 0.01 to about 5 wt % ethyl cellulose, b) from about 5 to about 70 wt % oil component(s), c) from... | 1. An agent for lightening keratin fibers, comprising relative to the weight thereof
a) from about 0.01 to about 5 wt % ethyl cellulose, b) from about 5 to about 70 wt % oil component(s), c) from about 1 to about 70 wt % peroxydisulphate(s) from the group of sodium peroxydisulphate and/or potassium peroxydisulphate and... | Agent for lightening keratin fibers and method for changing the color of keratinic fibers are provided herein. In an embodiment, an agent for lightening keratin fibers includes, relative to the weight thereof, a) from about 0.01 to about 5 wt % ethyl cellulose, b) from about 5 to about 70 wt % oil component(s), c) from... | 1,600 |
491 | 491 | 15,123,272 | 1,653 | A thin film culture device for detecting aerobic bacteria in a sample is provided. The culture device comprises a self-supporting substrate sheet having a first major surface and a second major surface; a cover sheet attached to the substrate sheet, a sample-receiving zone disposed between the substrate sheet and the c... | 1. A device for culturing and detecting microorganisms, the device comprising:
a self-supporting substrate sheet having a first major surface and a second major surface; a cover sheet attached to the substrate sheet; a sample-receiving zone disposed between the substrate sheet and the cover sheet; a first layer compris... | A thin film culture device for detecting aerobic bacteria in a sample is provided. The culture device comprises a self-supporting substrate sheet having a first major surface and a second major surface; a cover sheet attached to the substrate sheet, a sample-receiving zone disposed between the substrate sheet and the c... | 1,600 |
492 | 492 | 15,051,463 | 1,633 | Compositions and methods are disclosed herein for cloning a synthetic or a semi-synthetic donor genome in a heterologous host cell. In one embodiment, the donor genome can be further modified within a host cell. Modified or unmodified genomes can be further isolated from the host cell and transferred to a recipient cel... | 1. A method for seamlessly introducing a modification in a target nucleic acid molecule present in a host cell, comprising:
a. introducing a mutagenesis construct and a host vector into the host cell whereby the host vector recombines with the mutagenesis construct in the host cell, wherein the mutagenesis construct co... | Compositions and methods are disclosed herein for cloning a synthetic or a semi-synthetic donor genome in a heterologous host cell. In one embodiment, the donor genome can be further modified within a host cell. Modified or unmodified genomes can be further isolated from the host cell and transferred to a recipient cel... | 1,600 |
493 | 493 | 13,470,250 | 1,699 | A guided mode resonance (GMR) sensor that can be used to simultaneously detect an array of analytes. It provides a diagnostic system that can rapidly detect an array of biomarker proteins in patient samples (such as blood, serum or plasma for example) which can be used as an accurate means to conduct a differential ana... | 1. A biomarker sensor, comprising
GMR sensor assembly comprising: a waveguide structure configured for operation at or near one or more leaky modes; means for receiving input light from a source of light that includes one or more line focusing elements to focus input light onto the waveguide structure to cause one or m... | A guided mode resonance (GMR) sensor that can be used to simultaneously detect an array of analytes. It provides a diagnostic system that can rapidly detect an array of biomarker proteins in patient samples (such as blood, serum or plasma for example) which can be used as an accurate means to conduct a differential ana... | 1,600 |
494 | 494 | 14,904,199 | 1,619 | The present invention relates to a composition comprising, in a cosmetically acceptable medium, at least one water-insoluble solid organic UV-screening agent (A) at least one compound (B) that may be obtained by reaction between: an oil bearing at least one nucleophilic and/or electrophilic reactive function, and a jun... | 1. Composition comprising, in a cosmetically acceptable medium,
a) at least one water-insoluble solid organic UV-screening agent (A) and b) at least one compound (B) that may be obtained by reaction between:
an oil bearing at least one nucleophilic and/or electrophilic reactive function, and
a junction group capable of... | The present invention relates to a composition comprising, in a cosmetically acceptable medium, at least one water-insoluble solid organic UV-screening agent (A) at least one compound (B) that may be obtained by reaction between: an oil bearing at least one nucleophilic and/or electrophilic reactive function, and a jun... | 1,600 |
495 | 495 | 15,270,876 | 1,615 | This disclosure relates to medical devices incorporating one or more cationic steroidal antimicrobials (CSAs). The CSAs are incorporated into the medical devices to provide effective antimicrobial, anti-inflammatory, and/or tissue-healing properties. A medical device includes a component formed from a polymeric materia... | 1. An implantable medical device, the implantable medical device comprising:
a structural component formed at least in part from a polymeric material; and one or more CSA compounds, the one or more CSA compounds being incorporated into the polymeric material of the structural component so as to be distributed throughou... | This disclosure relates to medical devices incorporating one or more cationic steroidal antimicrobials (CSAs). The CSAs are incorporated into the medical devices to provide effective antimicrobial, anti-inflammatory, and/or tissue-healing properties. A medical device includes a component formed from a polymeric materia... | 1,600 |
496 | 496 | 15,407,037 | 1,635 | The present invention provides gapped oligomeric compounds. More particularly the gapped oligomeric compounds provided herein comprise at least one modified internucleoside linkage in the gap region. Such gapped oligomeric compounds have one or more improved properties such as selectivity, potency, improved toxicity pr... | 1. A gapped oligomeric compound comprising a contiguous sequence of linked monomer subunits having a gap region located between a 5′-region and a 3′-region wherein the 5′ and 3′-regions each, independently, have from 2 to 8 contiguous RNA-like modified nucleosides, each independently selected from a bicyclic nucleoside... | The present invention provides gapped oligomeric compounds. More particularly the gapped oligomeric compounds provided herein comprise at least one modified internucleoside linkage in the gap region. Such gapped oligomeric compounds have one or more improved properties such as selectivity, potency, improved toxicity pr... | 1,600 |
497 | 497 | 14,763,973 | 1,613 | The present invention provides a freshness-retentive film having high antibacterial characteristics. In the freshness-retentive film according to the present invention, at least one compound selected from the group consisting of palmityldiethanolamine, stearyldiethanolamine, glycerol monolaurate, and diglycerol monolau... | 1. A freshness-retentive film, comprising at least one compound selected from the group consisting of palmityldiethanolamine, stearyldiethanolamine, glycerol monolaurate, and diglycerol monolaurate, wherein the at least one compound is present on at least one surface at 0.002 to 0.5 g/m2. 2. The freshness-retentive fil... | The present invention provides a freshness-retentive film having high antibacterial characteristics. In the freshness-retentive film according to the present invention, at least one compound selected from the group consisting of palmityldiethanolamine, stearyldiethanolamine, glycerol monolaurate, and diglycerol monolau... | 1,600 |
498 | 498 | 13,729,631 | 1,615 | The invention relates to a composition, especially a cosmetic composition, comprising at least one silicon resin comprising at least one T unit and at least one acrylic film forming agent, as well as to methods of using such compositions. | 1. A composition comprising at least one film forming silicon resin comprising at least one T unit and at least one acrylic film forming agent. 2. The composition of claim 1, further comprising at least one wax. 3. The composition of claim 2, wherein the wax is a silicone wax. 4. The composition of claim 1, further com... | The invention relates to a composition, especially a cosmetic composition, comprising at least one silicon resin comprising at least one T unit and at least one acrylic film forming agent, as well as to methods of using such compositions.1. A composition comprising at least one film forming silicon resin comprising at ... | 1,600 |
499 | 499 | 14,419,149 | 1,632 | The invention relates to a method for culturing a subpopulation of circulating epithelial tumour cells from a body fluid of a human or animal suffering from an epithelial tumour, wherein cells contained in the body fluid each containing at least one cell nucleus are separated from the body fluid and cultured over at le... | 1. A method for culturing circulating epithelial tumor cells from a body fluid from a human or animal affected by an epithelial tumor, comprising:
separating cells present in the body fluid and containing at least one nucleus in each case are separated from the body fluid without selection of certain of these cells; tr... | The invention relates to a method for culturing a subpopulation of circulating epithelial tumour cells from a body fluid of a human or animal suffering from an epithelial tumour, wherein cells contained in the body fluid each containing at least one cell nucleus are separated from the body fluid and cultured over at le... | 1,600 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.